General considerations in intermittent drug therapy of pulmonary tuberculosis.
D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000995:Antitubercular Agents / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004977:Ethambutol / Q000008:administration & dosage; D005000:Ethionamide / Q000008:administration & dosage; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage; D011718:Pyrazinamide / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage; D013307:Streptomycin / Q000008:administration & dosage / Q000009:adverse effects; D013828:Thioacetazone / Q000008:administration & dosage; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D013828:Thioacetazone; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin